NCT02562131

PET-MR-PSA Prostate Cancer Recidive Study

18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: Norwegian University of Science and Technology · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in a single imaging session. The aim of this study is to evaluate the sensitivity and specificity of simultaneous 18F-Fluciclovine PET/MRI for detection of recurrent prostate cancer.

Detailed description

The patients follow standard treatment and follow-up after the PET/MRI exam, which will be determined by the patient's treating urologist and/or oncologist. Data from histopathology, clinical follow-up and follow-up imaging will be collected to establish a reference standard that defines the presence or absence of disease for each patient. The imaging findings will be compared with the reference standard to assess the sensitivity and specificity. The diagnostic accuracy of combined PET/MRI and MRI-only (the current clinical standard) will be compared.

Conditions

• Prostate Cancer Recurrent

Timeline

• Start date: 2015-09-01
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2015-09-29
• Last updated: 2025-06-06

Locations

1 site across 1 country: Norway